Bupropion for smoking cessation: a randomized trial.

What Was Tested

Researchers studied Nicotine and Bupropion in this randomized controlled trial publication.

Who Took Part

According to the abstract, 244 participants were involved.

The age groups tagged for this paper are middle-aged adults, both men and women.

A total of 244 current smokers were enrolled in an outpatient randomized blinded smoking cessation trial conducted at the San Francisco Veterans Affairs Medical Center, San Francisco, Calif.

All participants received 2 months of transdermal nicotine replacement therapy and 3 months of cognitive-behavioral counseling.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Nicotine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Nicotine study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Nicotine could be set against what happens without it.

The researchers determined on-medication treatment, end-of-medication treatment, 3-month, 6-month, and 1-year quit rates.

What Was Measured

PubMed files the paper under topics including Antidepressive Agents, Second-Generation, Bupropion, Logistic Models, Multivariate Analysis, Nicotine, Placebo Effect and Risk.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Nicotine and Bupropion in 244 participants.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Archives of internal medicine), a journal based in United States.

More context: the related Therapeutic nicotine (patch, non-peptide) library page, all human trials.